Rahul Kumar: Promising for Lymphoma Patients Who’ve Failed Prior CAR-T
Rahul Kumar, Medical Oncology Trainee at AIIMS, New Delhi, shared a post on X about a paper by Jakub Svoboda et al. published in NEJM:
“Promising for lymphoma patients who’ve failed prior CAR-T: phase 1 trial; huCART19-IL18, an IL-18 armored CAR T-cell
81% ORR
51% CR
less toxicity (mostly G1/2)
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure.”
Title: Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
Authors: Jakub Svoboda, Daniel J. Landsburg, James Gerson, Sunita D. Nasta, Stefan K. Barta, Elise A. Chong, Michael Cook, Noelle V. Frey, Joanne Shea, Amanda Cervini, Amy Marshall, Megan Four, Megan M. Davis, Julie K. Jadlowsky, Anne Chew, Edward Pequignot, Vanessa Gonzalez, Julia Han Noll, Luca Paruzzo, Juliana Rojas-Levine, Gabriela Plesa, John Scholler, Donald L. Siegel, Bruce L. Levine, David L. Porter, Saba Ghassemi, Marco Ruella, Andrew Rech, Rachel M. Leskowitz, Joseph A. Fraietta, Wei-Ting Hwang, Elizabeth Hexner, Stephen J. Schuster, Carl H. June.
You can read the Full Article in NEJM.
More posts featuring Rahul Kumar.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023